Press releases

4 May, 2023

Regulatory

Amendment of the Nomination Committee’s proposal for Abliva’s Annual General Meeting in 2023

The notice for Abliva’s Annual General Meeting (AGM) 2023 was announced in a press release on April 4th, 2023. The Nominating Committee’s proposal for the election of Board members was [&h ...

17 April, 2023

Abliva’s Drug Candidate NV354 Granted Orphan Drug Designation for the Treatment of Mitochondrial Disease

Abliva AB (Nasdaq Stockholm: ABLI), a clinical-stage company developing medicines for the treatment of rare and severe primary mitochondrial diseases, today announced that the drug candidate NV354 has ...

4 April, 2023

Regulatory

Notice of Annual General Meeting of Abliva AB (publ)

The shareholders of Abliva AB (publ), corporate identity number 556595-6538, are hereby convened to the Annual General Meeting, held at 10 a.m. on Friday, 5 May 2023 at Medicon Village, Scheeletorget ...

31 March, 2023

Regulatory

Abliva AB Publishes 2022 Annual Report

Abliva AB (Nasdaq Stockholm: ABLI), a clinical-stage biotech company developing medicines for the treatment of rare and severe primary mitochondrial diseases, today announced that the English version ...

16 March, 2023

BioStock Investor Meeting with Abliva

Do not miss Abliva's presentation at the BioStock Investor Meeting, today March 16 at 10.00 am. The event starts at 10.00 - see the full programme on BioStock's website or YouTube channel.

8 March, 2023

Regulatory

Resolutions at the Extraordinary General Meeting in Abliva AB (publ)

Abliva AB (Nasdaq Stockholm: ABLI) (”Abliva” or the ”Company”) has today held an Extraordinary General Meeting. A summary of the resolutions follows.

24 February, 2023

Regulatory

Abliva AB Year-End Report January – December 2022

A successful financing enabled the start of the FALCON study with KL1333

13 February, 2023

Regulatory

Notice of Extraordinary General Meeting of Abliva AB (publ)

The shareholders of Abliva AB (publ), corporate identity number 556595-6538, are hereby convened to the Extraordinary General Meeting (the “EGM”) to be held at 11.00 a.m. on Wednesday 8 March 2023 at ...

13 February, 2023

Regulatory

Abliva Nomination Committee to propose Edwin Moses as a new Board member and incoming Chair of the Board of Directors at upcoming General Meetings

The Nomination Committee of Abliva AB proposes that Dr. Edwin Moses be elected as a new Board member of the Company through a shareholder vote at the EGM on March 8, 2023. Dr. Moses, who has over 30 y ...

9 February, 2023

Abliva

Press releases

Amendment of the Nomination Committee’s proposal for Abliva’s Annual General Meeting in 2023

Abliva’s Drug Candidate NV354 Granted Orphan Drug Designation for the Treatment of Mitochondrial Disease

Notice of Annual General Meeting of Abliva AB (publ)

Abliva AB Publishes 2022 Annual Report

BioStock Investor Meeting with Abliva

Resolutions at the Extraordinary General Meeting in Abliva AB (publ)

Abliva AB Year-End Report January – December 2022

Notice of Extraordinary General Meeting of Abliva AB (publ)

Abliva Nomination Committee to propose Edwin Moses as a new Board member and incoming Chair of the Board of Directors at upcoming General Meetings

Abliva Announces Issuance of a New U.S. Patent for Therapeutic Compound NV354

Abliva Appoints Dag Nesse as Vice President of Clinical Operations

Abliva initiates the global FALCON study with lead candidate KL1333